Clinical Trial: NCT07793435
A Phase 1/2 Trial of ADI-212 in mCRPC
Status:
NOT YET RECRUITINGPhase:
Phase 1| Lead Sponsor: | Adicet Therapeutics |
| Information Provided By: | Adicet Therapeutics |
| Last Update Posted: | 2026-09-10 |
Study Overview
Brief Summary
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)
Official Title
A Phase 1/2 Trial of ADI-212 (Engineered γδ Chimeric Antigen Receptor [CAR] Vδ1 T Cells Targeting PSMA) in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions
Prostate Cancer Metastatic
Intervention / Treatment
- Drug: ADI-212
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- ADI-212-001
Start Date (Estimated)
2026-09
Primary Completion Date (Estimated)
2028-10
Study Completion Date (Estimated)
2029-10
Enrollment (Estimated)
12
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | Adicet Therapeutics |
| Information Provided By: | Adicet Therapeutics |
| Last Update Posted: | 2026-09-10 |
Study Overview
Brief Summary
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)
Official Title
A Phase 1/2 Trial of ADI-212 (Engineered γδ Chimeric Antigen Receptor [CAR] Vδ1 T Cells Targeting PSMA) in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions
Prostate Cancer Metastatic
Intervention / Treatment
- Drug: ADI-212
- Drug: Fludarabine
- Drug: Cyclophosphamide
Other Study ID Numbers
- ADI-212-001
Start Date (Estimated)
2026-09
Primary Completion Date (Estimated)
2028-10
Study Completion Date (Estimated)
2029-10
Enrollment (Estimated)
12
Study Type
Interventional
Phase
Phase 1, Phase 2